000 02194nam  2200421zi 4500
0019.894118
003CaOODSP
00520230925103305
006m     o  d f      
007cr cn|||||||||
008201127t20212019onc     o    f000 0 eng d
020 |a9780660367620
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-305/2021E-PDF
24500|aGuidance document : |bcertificates of supplementary protection.
24610|aCertificates of supplementary protection
24617|aCSP guidance document
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |c2021.
264 4|c©2019
300 |a1 online resource (25 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |aIssued also in HTML format.
500 |a"Effective date: 2021/01/06."
500 |aIssued also in French under title: Ligne directrice : certificats de protection supplémentaire.
520 |a"In agreeing to provisionally apply the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada has committed to provide up to two years of sui generis protection for new pharmaceutical products protected by an eligible patent, from the expiry of the patent. Canada has implemented this commitment by introducing Certificates of Supplementary Protection (CSPs) for medicinal ingredients, applicable for Canadian pharmaceuticals, biologics and veterinary drugs"--Introduction, page 7.
650 0|aPatent medicines|zCanada.
650 0|aPatent extensions|zCanada.
650 0|aPharmaceutical policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLigne directrice : |w(CaOODSP)9.894119
794 |tGuidance document : |w(CaOODSP)9.921627
85640|qPDF|s337 KB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H164-305-2021-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/register-certificates/certificate-supplementary-protection-regulations.html